JP Morgan Chase
FULC icon

JP Morgan Chase’s Fulcrum Therapeutics FULC Stock Holding History

JP Morgan Chase’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,800
Closed -$22.6K – 7443
2024
Q4 		$22.6K Hold
4,800
– – ﹤0.01% 6229
2024
Q3 		$17.1K Sell
4,800
-4,000
-45% -$29.7K ﹤0.01% 6266
2024
Q2 		$54.6K Buy
+8,800
New +$66.7K ﹤0.01% 5818

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's FULC Position: Q2 2026 in Review

JP Morgan Chase increased its Fulcrum Therapeutics (FULC) stake by 39% in Q2 2026, buying an estimated $70.4K and bringing the position to 41,371 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #5764.

JP Morgan Chase first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. The position peaked at $4.9M in Q3 2021. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • JP Morgan Chase held 41,371 shares of Fulcrum Therapeutics worth $154K as of Q2 2026.
  • JP Morgan Chase bought 11,579 Fulcrum Therapeutics shares in Q2 2026, an estimated $70.4K.
  • Fulcrum Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5764 holding.
  • JP Morgan Chase first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Fulcrum Therapeutics position peaked at $4.9M in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.